[Genetic polymorphisms as tool indicators for individual vulnerability to smoking behaviour]
Related Experiment Video
Updated: May 16, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Carme Barrot1, Cristina Sánchez, Rosa Abellana
1Laboratorio de Genética, Unidad de Medicina Legal y Toxicología, Departamento de Salud Pública, Facultad de Medicina, Universidad de Barcelona, Barcelona, España. cbarrotfeixat@ub.edu
Background And Objectives:
In line with genetic and pharmacological studies suggesting that neurotransmitter pathways play a role in nicotine dependence, research was conducted in connection with 4 genetic polymorphisms: OPRM1, TPH1, ADRA2A and HTR1B. This study compares the genotype and allele frequencies in 3 groups (non-smokers, former smokers and smokers) of unrelated individuals (n=490) from Catalonia (north east Spain) in order to find any relationship.
Material And Methods:
All polymorphisms were genotyped in each population group and statistical analysis was performed.
Results:
Data obtained show that there is a relationship between sex, age and the TPH1 locus, indicating a trend towards a lower frequency of the AA genotype in former smokers for the TPH1 locus.
Conclusions:
The results indicate that a role is played by the TPH1 polymorphism as an indicator of therapeutic failure in smoking cessation.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
